Member Posts > Cardiol Therapeutics' CRD-38: A Next-Generation Therapy That Could Redefine HF Treatment
🩺 Cardiol Therapeutics (NASDAQ: CRDL) has unveiled new JACC-backed data, reinforcing CRD-38's potential to transform heart failure treatment.
📌 How CRD-38 Stands Out:
✔ Reduces Chronic Inflammation - A key driver of HF disease progression.
✔ Enhances Oxygen Delivery - Organic nitrates support vascular relaxation and blood flow.
✔ Subcutaneous Delivery - More reliable absorption and improved patient adherence over oral meds.
🔬 What Preclinical Research Shows:
📈 Better Heart Function - Increased ejection fraction and overall circulation efficiency.
📉 Lower Fibrosis & Hypertrophy - Less cardiac damage over time.
💡 The Future of HF Treatment?
CRD-38 is tackling HF at its core, rather than just managing symptoms-potentially setting a new benchmark in cardiovascular medicine.

#CardiolTherapeutics #BiotechInvesting #ClinicalTrials #PharmaStocks #CBDTherapeutics #HeartHealth #StockMarket #InvestingInBiotech #HealthcareInnovation #OrphanDrug #Myocarditis #Pericarditis #FDAApproval #GrowthStocks #MedicalBreakthroughs #CRD38 #CardiolRx